Add a drug when the blood test turns, without stopping the one that works
When a resistance mutation first appears in the blood, the current drug is often still controlling most of the tumour. Adding a second drug rather than swapping may keep both under control.
Most ctDNA-guided strategies switch therapy at molecular progression. Because the resistant clone is usually a minority at that point, switching abandons control of the sensitive majority. An additive strategy keeps the backbone and adds a mechanism-matched agent when a specific resistance alteration crosses a threshold in plasma, with the aim of suppressing both populations.
- Acquired resistance to every therapy · Nearly every targeted therapy stops working within months to a few years as the tumour adapts.
- Trial design, endpoints and cost · A phase 3 trial takes years and hundreds of millions of dollars, and often answers a question that has already moved on.
Pages like this
not linked directly; found by shared links- IdeaAdd the second drug on day one when the escape route is predictable
Shares Amivantamab, MET, Osimertinib, Acquired resistance to every therapy.
- PersonDae Ho Lee
Shares Amivantamab, MET, Osimertinib, EGFR.
- IdeactDNA-guided dose holidays for lung cancer targeted therapy
Shares Osimertinib, Acquired resistance to every therapy, EGFR, Liquid biopsy (ctDNA).
- IdeaA clone report from blood at every treatment cycle
Shares Molecular-progression switching beyond ESR1, Osimertinib, Acquired resistance to every therapy, Liquid biopsy (ctDNA).
- PairingAmivantamab + lazertinib (first-line EGFR NSCLC)
Shares Amivantamab, MET, Osimertinib, EGFR.
- TermMET amplification (bypass resistance)
Shares Amivantamab, MET, Acquired resistance to every therapy, EGFR.
- TrialLAURA
Shares Osimertinib, EGFR, Non-small-cell lung cancer.
- IdeaPause a failed drug so the tumour becomes sensitive to it again
Shares Osimertinib, Acquired resistance to every therapy, Liquid biopsy (ctDNA), Non-small-cell lung cancer.